

**PATENT**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

U. S. Patent No. : 7423037 B2  
Issued: : September 9, 2008  
First Applicant : CAMPBELL Gordon Iain  
Serial No. : 10/577841  
Application Date : October 28, 2004  
US Nat'l Entry Date : April 29, 2006  
Entitled : MORPHOLINE DERIVATIVES AS NOREPINEPHRINE  
REUPTAKE INHIBITORS  
Docket No. : X15830

**REQUEST FOR CERTIFICATE OF CORRECTION**  
**UNDER 37 C.F.R. 1.322**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The patentees of the above-identified patent respectfully request that you issue a Certificate of Correction to correct errors which occurred during the printing of the patent. The printing errors are not errors of the patentee as evidenced by, for example, the transmittal letter which was signed and submitted by Charles E. Cohen on 27 April 2006, item 18. Attached is a copy of Form PTO 1050 on which the errors are specified.

Respectfully submitted,  
/Nelsen L. Lentz/

Nelsen L. Lentz  
Attorney/Agent for Applicant(s)  
Registration No. 38,537  
Phone: 317-276-1207

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288  
August 30, 2010

---

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

Page 1 of 1

PATENT NO. : 7,423,037 B2  
DATED : September 9, 2008  
FIRST APPLICANT: CAMPBELL, Gordon Iain, et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the issued patent, please note the following corrections:

On Title page should read,

Insert Item -- [60] **Related U.S. Application Data**

Provisional application No. 60/535,459, filed on January 9, 2004 --

On the first page of the specification, insert the following cross-reference after the title:

-- This is the national phase application, under 35 USC 371, for PCT/US2004/032771, filed 28 October 2004, which claims the benefit of GB provisional application 0326148.4, filed 10 November 2003 and US provisional application 60/535,459, filed 09 January 2004.--

MAILING ADDRESS OF SENDER:

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

PATENT NO. 7,423,037 B2